期刊
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
卷 32, 期 6, 页码 1343-+出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/ATVBAHA.112.247726
关键词
kidney; nitric oxide; nitric oxide synthase; vascular biology; asymmetric dimethylarginine
资金
- Academy of Medical Sciences
- Welcome Trust
- British Heart Foundation
- Medical Research Council
- Academy of Medical Sciences (AMS) [AMS-SGCL5-Caplin] Funding Source: researchfish
- Medical Research Council [MC_U120097118] Funding Source: researchfish
- National Institute for Health Research [CL-2010-18-001] Funding Source: researchfish
- MRC [MC_U120097118] Funding Source: UKRI
The asymmetric methylarginines inhibit nitric oxide synthesis in vivo by competing with L-arginine at the active site of nitric oxide synthase. High circulating levels of asymmetric dimethylarginine predict adverse outcomes, specifically vascular events but there is now increasing experimental and epidemiological evidence that these molecules, and the enzymes that regulate this pathway, play a mechanistic role in cardiovascular diseases. Recent data have provided insight into the impact of altered levels of these amino acids in both humans and rodents, however these reports also suggest a simplistic approach based on measuring, and modulating circulating asymmetric dimethylarginine alone is inadequate. This review outlines the basic biochemistry and physiology of endogenous methylarginines, examines both the experimental and observational evidence for a role in disease pathogenesis, and examines the potential for therapeutic regulation of these molecules. (Arterioscler Thromb Vasc Biol. 2012;32:1343-1353.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据